We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Urology

Journal Scan / Research · November 21, 2020

Pembrolizumab for the Treatment of Patients With Bacillus Calmette-Guérin Unresponsive, High-Risk Non–Muscle-Invasive Bladder Cancer

Journal of Clinical Oncology

 

Additional Info

Journal of Clinical Oncology
Pembrolizumab (pembro) for the Treatment of Patients With Bacillus Calmette-Guérin (BCG) Unresponsive, High-Risk (HR) Non–Muscle-Invasive Bladder Cancer (NMIBC): Over Two Years Follow-Up of KEYNOTE-057
J. Clin. Oncol 2020 May 20;38(15_suppl)5041, AV Balar, AM Kamat, GS Kulkarni, EM Uchio, JL Boormans, DF Bajorin, M Roumiguié, EA Singer, LEM Krieger, P Grivas, HK Seo, H Nishiyama, BR Konety, K Nam, JP Zambon, E Kapadia, R De Wit

Further Reading